This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,080
Once daily, 7AM - 10AM
Once daily, 7AM - 10AM
Peking University People's Hospital
Beijing, China
Proportion of patients who reach overall blood pressure control (defined as BP <140/90 mmHg for non-diabetic patients and < 130/80 mmHg for diabetic patients)
Time frame: Week 8
Change from baseline in systolic blood pressure (SBP)
Time frame: Week 8
Change from baseline in diastolic blood pressure (DBP)
Time frame: Week 8
Incidence of adverse effects
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.